UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Diffuse Midline Glioma
This study will enroll children and young adults (between the ages of 3 to 21 years old) with newly diagnosed Diffuse Midline Gliomas (DMGs, HLA-A*0201 positive and H3.3K27M positive).
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Medulloblastoma
Choroid Plexus Tumors
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The purpose is to evaluate cognitive, social, emotional, and behavioral functioning over time in patients already enrolled in a Children’s Oncology Group Phase III clinical trial.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma (grade IV)
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary
This phase I/II clinical trial will evaluate REGN2810 (also called cemiplimab) in combination with radiation therapy as a treatment for pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), ne
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Medulloblastoma
Oligodendroglioma
Pilocytic astrocytoma (grade I)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Brainstem Glioma
Diffuse Midline Glioma
Pineal Region Tumors
This phase II clinical trial tests the use of a precision medicine approach in treating pediatric patients with recurrent solid tumors, including central nervous system tumors.